At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 6 enrolled
Drug / intervention
Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virusbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-VMD2-hMERTK) Gene Vector to Patients With Retinal Disease Due to MERTK Mutations
In Brief
A Phase 1 clinical trial evaluating Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus for Retinal Disease and Retinitis Pigmentosa. Completed, enrolled 6 participants across 1 site.
Detailed Summary
This study was to assess the safety of gene transfer via subretinal administration of rAAV2-VMD2-hMERTK in subjects with MERTK-associated retinitis pigmentosa (RP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRetinal Disease, Retinitis Pigmentosa
CountriesSaudi Arabia
CollaboratorsKing Faisal Specialist Hospital & Research Center
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2011
First PostedNov 2011
Primary CompletionAug 2013
Study CompletionAug 2019
TodayJul 2026
First PostedNov 30, 2011
Enrollment StartAug 1, 2011
Primary CompletionAug 1, 2013
Study CompletionAug 1, 2019
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 14.6 years ago
Interventions
Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virusbiological
The study is an open-label, dose-escalation, phase I clinical trial of subretinal administration of rAAV2-VMD2-hMERTK in patients with retinitis pigmentosa due to MERTK mutation.